Subject Index

(A) = Abstracts, 4th Annual Meeting of the International Society of Blood Purification

Acetate, chronic administration 217 (A)

Acute renal failure, see CAVH

Aluminum
- - deferoxamine 226 (A), 227 (A), 230 (A)
- - - infusion and high-performance dialysis
231 (A) Arteriovenous hemodiafiltration, CAVH and hemoperfusion 221 (A) Ascites, ultrafiltration 224 (A) Autonomic nervous system, parathyroidectomy 215 (A)

Bicarbonate
balance, dialysis patients 216 (A)
hemofiltration, 2-years experience 212(A)

Biocompatibility
- - cellophane 93
- - cellulose acetate 93, 225 (A)
- - - polyacrylonitrile, polysulfone,
polycarbonate membranes 93 - , cuprophan 225 (A)
- - ethylenepolyvinylalcohol 225 (A)
- - polyacrylonitrile 93, 185, 225 (A)
- - polyamide 204 (A)
- - polycarbonate-polyether, and other membranes
74, 82, 88, 93, 102, 112, 142, 147, 151, 159, 168.
185 - , polymethylmethacrylate 225 (A) - , polysulfone 93
- - secondary polymer coating 206 (A) - , various membranes 207 (A) Biofiltration, clinical results 219 (A) Blood purification, multiple organ failure
224 (A) Body weight changes, neural transmission, dialysis patients 217 (A)

Caffeine, autonomic function, uremic subjects
219(A) CAPD
- - amino acid solutions 226 (A) - , bactericidal effluents 210(A)

Subject Index

235

- - cellular immunity 209 (A)
- - complement activation 210(A)
- - efficacy of peritoneal transport 194
Cardiovascular adaptation, ultrafiltration below normovolemic state 216(A) CAVH
Acute renal failure 223 (A)
blood flow dynamics, ultrafiltration kinetics
220 (A)
characterization of different hemofilters 222 (A)
combined with arteriovenous hemodiafiltration
and hemoperfusion 221 (A)
drug sieving coefficients 221 (A)
filtrate line suction maneuvers 221 (A)
high performance 222 (A)
poly sulfone hemofilter 220 (A)
predilution fluid replacement 222 (A) Cell-mediated immunity, see α-Hydroxyvitamin D3
Cellophane, see Biocompatibility Cellular immunity, CAPD and HD 209 (A) Cellulose acetate,
see Biocompatibility Cellulose ester, complement activation 185 Cellulosic membranes,
adaptability to changing
demands 205 (A) Ceramic membranes, low-temperature plasma
separation 228 (A) Chromium, metabolism, chronic hemodialysis
227 (A)
Coagulation system, dialysis membranes 130 Complement activation
clinical effects, HD patients 206 (A)
cellulose ester 185
cuprophan 185
copoly acrylonitrile 185
copolyamide membrane 204 (A)
copoly carbonate-polyether membrane 74, 82,
88,93,102,112,142,151,159,168,185
- -, polymethylmethacrylate membrane 185
- -, hemodialysis-induced activation 185
Cryoglobulinemia, membrane plasmapheresis 228 (A)
Cuprammonium rayon, high-flux hemodialysis
225 (A) Cuprophan -, see Biocompatibility
- -, hemodynamics 102
- -, complement activation 185
- -, 5 μm thick membrane 225 (A)
- -, limulus amebocyte lysate test 208 (A)
Cyclooxygenase, production during HD 207 (A)
Deferoxamine aluminum
- -, associated bone disease 226 (A)
- -, iron overload 227 (A)
- -, related osteodystrophy 231(A)
- -, removal by different methods of blood
purification 230 (A) Dialysis membranes
- -, coagulation system 130
- -, interleukin production 231 (A) Drug sieving coefficients, CAVH 221 (A)
Erythropoiesis, peptide inhibitor, uremia
211(A) Ethylene-oxide-induced IgE antibodies,
hypersensitivity reactions 206 (A) Ethylen vinyl alcohol, see Biocompatibility
Glomerular capillary wall, engineering analysis 214 (A)

Hemodiafiltration
- adequacy 218 (A)
- autonomic function 219 (A)
- hard and soft HDF 219 (A)
- hemodynamic changes 216 (A)
- highly permeable membrane 210 (A)
- in-line production, substitution fluid 218 (A)
- push/pull method 218 (A)

Hemodialysis
- autonomic function 219 (A)
- calculated bicarbonate balance 216 (A)
- cellular immunity 209 (A)
- chromium metabolism 227 (A)
- complement activation, polycarbonate membrane 74, 82, 88, 93, 102, 112, 142, 147, 151, 159, 168
- continuous arteriovenous nonmachinery 224 (A)
cuprammonium rayon membrane 225 (A)
cyclooxygenase and lipoxygenase production 207 (A)
development of a new plate dialyzer 6
hemodynamic changes 216 (A)
immune abnormalities 120
manganese levels 227 (A)
membranes, complement activation 185
β2-microglobulin kinetics 210 (A)
new polycarbonate-polyether membrane 47, 53
polycarbonate-polyether flat plate dialyzer 6, 32, 40, 63, 142
- hollow-fiber membrane 23, 112
236

Subject Index

Hemodynamic changes, HD, HDF, sequential ultrafiltration 216 (A) Hemofilters - CAVH 222 (A), reuse 213 (A) Hemofiltration
- autonomic nervous function 219 (A), encephalopathy, fulminant hepatitis 223 (A)
- excessive protein loss 214 (A), in-line prepared substitution fluid 213 (A)
- β2-microglobulin kinetics 210 (A)
- portable artificial kidney 214 (A)
- predilution mode and low-flow 220 (A)
Hepatic encephalopathy, hemofiltration 223 (A)
Hollow-fiber polycarbonate membrane, hemodialysis 23, 112 α-Hydroxyvitamin D3, cell-mediated immunity 230 (A)
Interleukin-
- production by different membranes 231 (A)
- role of membrane and acetate 208 (A)
Iron, deferoxamine 227 (A)
Killer cells activity, dialysis membranes 204 (A)
Leukocyte degranulation, cuprophan and polycarbonate membranes 147 Lipoprotein lipase, urinary inhibitors 229 (A) Lipoxigenase, production during HD 207 (A) Manganese, levels during dialysis 227 (A) Mass transfer area coefficients, CAPD 194 Membrane-specific adsorption, solute elimination 211 (A) Microglobulin elimination 211 (A) kinetics, HD and HF 210 (A) levels, maintenance dialysis 212 (A) removal, dialysis patients 212 (A) Monocyte interleukin-1, Escherichia coli microfiltrate 207 (A) Monocytes, membrane biocompatibility 205 (A) Mononuclear phagocytic cell activation, acetate, lactate, bicarbonate 208 (A) Multiple myeloma, plasma exchange 228 (A) Parathyroidectomy - autonomic nervous system 215 (A) cardiovascular function 215 (A) Peritoneal transport, CAPD 198 Phosphatemia, meaning in dialysis patients 213 (A) Plasma exchange, multiple myeloma 228 (A) separation, ceramic membranes 228 (A) volume, sequential ultrafiltration-hemodialysis 215 (A) Plasmapheresis, cryoglobulinemia 228 (A) Platelet dysfunction, maintenance dialysis 229 (A) Polycrylonitrile, see Biocompatibility Polyamide, see Biocompatibility Polymethylmethacrylate - complement activation 185 - performance and biocompatibility 225 (A) Polycarbonate-polyether - see Biocompatibility - biocompatibility and hemodynamics 102 - clinical investigation of a new dialyzer 32, 40, 47, 53, 63, 74, 88, 93, 142 - coagulation system 130 - complement activation 74, 82, 88, 93, 102, 112, 142, 151, 159, 168, 185 - design of a new dialyzer 13 - leukocyte degranulation 147 - new hollow-fiber membrane 23, 112 Polysulfone - see Biocompatibility - CAVH 223 (A) Predilution fluid replacement, CAVH 222 (A) Prostaglandins - blood pressure 215 (A) - end-stage renal disease 215 (A) Protein loss, hemofiltration 214 (A) Regenerative artificial reticuloendothelial system, therapeutic use 229 (A) Renal failure, immune abnormalities 120 Secondary polymer coating, dialyzer biocompatibility 206 (A) Sequential ultrafiltration-hemodialysis, plasma volume changes 215 (A) Ultrafiltration - hypovolemia 216 (A) - intractable ascites 224 (A) Urea kinetic modeling, dialysis strategy control 226 (A)